Pfizer's new product Naxcel™ which will be part of their theme at the British Pig & Poultry Show

The sustained release formulation of the broad-spectrum antibiotic ceftiofur, Naxcel is licensed for treating Streptococcus suis lameness and septicaemia as well as swine respiratory disease caused by Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis in young and growing pigs.

Naxcel is the latest in the range of Pfizer products including the antibiotic Draxxin™ and the Mycoplasma hyopneumoniae vaccine Stellamune™ Once which have been developed to bring the benefits of using a single-dose, full-course approach in preventing and treating disease.

"What makes Naxcel so special is that, unlike conventional antibiotics, it rapidly reaches therapeutic plasma levels within one hour and remains active for at least 7 days, so that treatment is both fast acting and long lasting," says Marcon Tigges, product manager for Pfizer's pig and poultry team.

For the poultry industry the focus will be on Linco-Spectin™ Soluble Powder with its proven success against mycoplasma and bacterial infections which has led to healthier broilers and a substantial saving in rejects at the processing plant for a number of companies.